Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Philogen S.p.A.
Philogen Considers Partnering As Two Lead Assets Near Market
The Swiss-Italian biotech firm’s two lead assets for cancer are expecting pivotal readouts next year, prompting it to consider partnering strategies and further substantiating its targeted R&D approach.
Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program
AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.
Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Philogen Raises €62m To Advance Pipeline, Expand GMP Capacity
Philogen CEO Dario Neri tells Scrip the company he co-founded now has two oncology products in Phase III development and might consider partnering them for certain indications.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Philochem AG
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.